Cyclin-dependent kinase inhibitors in combination with anthracyclines for treatment of cancer
AssigneeTolero Pharmaceuticals, Inc.
InventorsDavid J. Bearss, Steven L. Warner, Clifford J. Whatcott
Life of this patent
Estimating the term…
Abstract
Methods for treating cancer by administration of two or more therapeutic agents are provided. The two or more therapeutic agents include a cyclin-dependent kinase inhibitor (e.g., alvocidib) and an anthracycline (e.g., daunorubicin or idarubicin). Kits comprising the two or more therapeutic agents that can be used to perform such methods are also provided.
Claims30
A method for treating a hematologic cancer in a subject in need thereof, the method comprising administering to the subject a treatment comprising an effective amount of each of:
- alvocidib, or a pharmaceutically acceptable salt thereof, or a prodrug of the foregoing;
- daunorubicin or idarubicin, or a pharmaceutically acceptable salt of the foregoing;
- and
- cytarabine, or a pharmaceutically acceptable salt thereof.
A method for treating previously untreated acute myeloid leukemia (AML) in a subject in need thereof, the method comprising administering to the subject a treatment comprising:
- from about 5 mg/m2 to about 50 mg/m2 alvocidib, or a pharmaceutically acceptable salt thereof, per day, administered by an intravenous bolus of from about 10 minutes to about 60 minutes in duration, and from about 10 mg/m2 to about 65 mg/m2 alvocidib, or a pharmaceutically acceptable salt thereof, per day, administered by intravenous infusion of about 4 hours in duration, wherein the intravenous bolus and the intravenous infusion of alvocidib, or a pharmaceutically acceptable salt thereof, are administered to the subject on the first, second and third days of the treatment, and the intravenous infusion is initiated about 30 minutes after completion of the intravenous bolus;
- from about 45 mg/m2 to about 110 mg/m2 daunorubicin, or a pharmaceutically acceptable salt thereof, per day, administered by intravenous bolus of from about 5 minutes to about 30 minutes in duration on the fifth, sixth and seventh days of the treatment;
- and
- from about 90 mg/m2 to about 110 mg/m2 cytarabine, or a pharmaceutically acceptable salt thereof, per day, administered by intravenous infusion of from about 20 hours to about 28 hours in duration on the fifth, sixth, seventh, eighth, ninth, tenth, and eleventh days of the treatment,
- wherein the treatment results in the subject being measurable residual disease (MRD)-negative.
Dependencies are inferred from the claim text.